Institutional members access full text with Ovid®

Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children

ZANGWILL, KENNETH M. MD; DROGE, JESSICA PhD*; MENDELMAN, PAUL MD; MARCY, S. MICHAEL MD; PARTRIDGE, SUSAN RN, MBA; CHIU, CHUNG-YIN MS; JING, JENNIE MS; CHANG, SWEI-JU MS; CHO, IKSUNG MS; WARD, JOEL I. MD

Pediatric Infectious Disease Journal: August 2001 - Volume 20 - Issue 8 - pp 740-746
Original Studies

Background. Trivalent formulations of an experimental, cold-adapted, intranasal influenza (CAIV) vaccine have been shown to be safe, immunogenic and efficacious in young children.

Methods. We evaluated the safety and immunogenicity of three consistency lots of CAIV in children 12 to 36 months of age randomized to one of five groups: Groups 1, 2 and 3 received separate lots containing A/Shenzhen/227/95 (H1N1), A/Wuhan/359/95(H3N2) and B/Harbin/7/94-like viral strains. Group 4 received an earlier efficacy trial lot which included a different H1N1 strain (A/Texas/36/91-like); and Group 5 received placebo. We performed strain-specific serum hemagglutination inhibition antibody levels against type A (H3N2 or H1N1) or type B as appropriate.

Results. Overall 474 children received 2 doses, 2 months apart. Each lot was well-tolerated, and there were no significant group differences between consistency lots in the proportion of children with fever and local or systemic reactions after vaccination. The 3 consistency lots were not statistically different with regard to immunogenicity as measured by seroconversion or absolute geometric mean titer. Immune responses were more robust among initially seronegative children and for H3N2 and B strains than for H1N1 strains. After 2 doses of vaccine 97, 84 and 62% had hemagglutination inhibition titers ≥1/32 against A/H3N2, B and H1N1 strains, respectively. For A/H3N2 only, immune responses after 1 dose of vaccine are similar to those seen after 2 doses.

Conclusions. Each consistency lot of CAIV is as or more immunogenic than a lot used in a large efficacy trial.

From the UCLA Center for Vaccine Research, Harbor-UCLA Medical Center, Torrance (KMZ, JD, SMM, SP, CYC, JJ, SJC, JIW); Southern California Kaiser Permanente Health Care Program, Panorama City (SMM); and Aviron, Mountain View (PM, IC), CA.

Accepted for publication Feb. 26, 2001.

*Current address: Theracardia, Inc., 1062F Calle Negocio, San Clemente, CA 92673.

Reprints not available.

© 2001 Lippincott Williams & Wilkins, Inc.